$2.380
-0.039 (-1.65%)At close
LUNG News
LUNG Events
Pulmonx Reports Q2 Revenue of $22.75M, Exceeds Expectations
Reports Q2 revenue $22.75M, consensus $22.39M. "We are pleased with the progress we made in the second quarter executing our commercial strategy, advancing our clinical initiatives, and beginning to deliver the significant operating leverage we expected," said Glen French, President and Chief Executive Officer of Pulmonx. "With a fully staffed US sales leadership team, a more focused global commercial team, and a realigned cost structure, we are confident in our ability to return to year-over-year revenue growth and drive meaningful operating leverage while advancing our longer-term strategic priorities."
Pulmonx Expects 2026 Revenue of $90M to $92M
The company said, "Pulmonx continues to expect revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company now expects gross margin for the full year 2026 to be approximately 76%. Pulmonx now expects total operating expenses for the full year 2026 to fall within the range of $109 million to $111 million, inclusive of approximately $15 million of non-cash stock-based compensation. The Company continues to expect cash, cash equivalents, and marketable securities to decrease by approximately $23 million for the full year 2026 assuming no additional drawdowns under the Company's credit facility."
Pulmonx Expects 2026 Revenue Between $90 Million and $92 Million
The company said, "Pulmonx continues to expect revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company continues to expect gross margin for the full year 2026 to be approximately 75%. Pulmonx continues to expect total operating expenses for the full year 2026 to fall within the range of $113 million to $115 million, inclusive of approximately $19 million of non-cash stock-based compensation. The Company continues to expect cash, cash equivalents, and marketable securities to decrease by approximately $23 million for the full year 2026 assuming no additional drawdowns under the Company's credit facility."
Pulmonx Reports Q1 Revenue of $20.59M, Exceeding Expectations
Reports Q1 revenue $20.59M, consensus $20.43M. "During the first quarter we initiated our refreshed U.S. commercial strategies and continued to execute in our direct international markets. We are encouraged by early signs of progress from the actions we have taken to refocus our U.S. sales organization and advance our clinical programs," said Glen French, President and Chief Executive Officer of Pulmonx. "With a fully staffed global sales organization, we remain confident in our ability to drive sequential improvement in revenue growth, execute against our strategic priorities, and deliver meaningful operating leverage in 2026."
Pulmonx Expects 2026 Revenue of $90M to $92M
The company said, "Pulmonx expects revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company expects gross margin for the full year 2026 to be approximately75%. Pulmonx expects total operating expenses for the full year 2026 to fall within the range of $113 million to $115 million, inclusive of approximately $21 million of non-cash stock-based compensation. The Company expects cash, cash equivalents, and marketable securities to decrease by approximately $23 million for the full year 2026 assuming no additional drawdowns under the Company's recently closed credit facility."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.